Is resveratrol metabolized by cytochrome P450 enzyme CYP1B1?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, resveratrol is metabolized by CYP1B1

Resveratrol undergoes metabolism by the cytochrome P450 enzyme CYP1B1, which converts it to piceatannol, a compound with known anticancer activity. This metabolic pathway has been directly demonstrated in laboratory studies and represents an important mechanism for resveratrol's biological effects 1.

Metabolic Pathways of Resveratrol

Primary CYP Enzymes Involved

Resveratrol is metabolized by multiple cytochrome P450 enzymes, with CYP1B1 playing a confirmed role alongside other isoforms:

  • CYP1B1: Catalyzes the aromatic hydroxylation of resveratrol to produce piceatannol (3,5,3',4'-tetrahydroxystilbene), an antileukaemic agent and tyrosine kinase inhibitor 1
  • CYP1A2: Plays a major role in human liver metabolism, converting resveratrol to both piceatannol and another tetrahydroxystilbene metabolite (M1) 2
  • CYP1A1: Also participates in resveratrol hydroxylation reactions 2

Clinical Significance of CYP1B1 Metabolism

The CYP1B1-mediated conversion is particularly noteworthy because:

  1. CYP1B1 is overexpressed in a wide variety of human tumors 1
  2. The metabolite piceatannol has documented anticancer activity 1
  3. This provides a mechanistic explanation for resveratrol's cancer preventative properties—the parent compound is converted to an active anticancer agent specifically in tumor tissue where CYP1B1 is abundant 1

Modulation of CYP Expression by Resveratrol

Importantly, resveratrol also downregulates CYP1B1 expression in certain contexts. In inflamed human epidermis models, resveratrol treatment reduced CYP1B1 gene expression as part of its anti-inflammatory and barrier-protective effects mediated through aryl hydrocarbon receptor (AHR) pathway modulation 3. Similarly, resveratrol and its methoxy derivatives reduced CYP1B1 mRNA transcript and protein levels by 31-89% in breast epithelial cells 4.

Drug Interaction Considerations

While resveratrol is a substrate of CYP1B1, the primary concern for drug-drug interactions involves CYP3A4 inhibition rather than CYP1B1. Trans-resveratrol significantly inhibits CYP3A4/5 activity in micromolar concentrations through a non-competitive mechanism, presenting potential risks for food-drug interactions with CYP3A4 substrates 5. However, natural resveratrol derivatives do not carry the same interaction risk as the parent compound 5.

Key Caveat

The bidirectional relationship between resveratrol and CYP1B1—where resveratrol is both a substrate and a suppressor of CYP1B1 expression—suggests context-dependent effects that may vary based on tissue type, inflammatory status, and exposure duration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.